ATOSSA THERAPEUTICS, INC.
ATOSNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$37.1M | −$27.6M | −$31.4M | −$27.7M | −$20.5M | −$14.6M |
| Net income | −$34.8M | −$25.5M | −$30.1M | −$27.0M | −$20.6M | −$17.8M |
| Total assets | $47.6M | $76.4M | $96.3M | $123.5M | $141.3M | $42.8M |
| Total liabilities | $8.3M | $5.0M | $5.2M | $5.6M | $3.1M | $15.7M |
| Equity | $39.4M | $71.5M | $91.0M | $118.0M | $138.1M | $27.2M |
| EPS (diluted) | $-4.04 | $-3.04 | $-0.24 | $-0.21 | $-0.18 | — |
| Shares out. | 129.2M | 125.3M | 126.6M | 126.6M | 120.8M | 9.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −88.4%
- Return on assets
- −73.0%
- Return on capital (ROCE)
- −94.4%
- Liabilities / assets
- 17.3%
- Debt / equity
- 0.21×
- Book value / share
- $0.30
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -11.97distress
- Accruals / assets
- −10.5%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Jul 29, 2025
- Blackrock, Inc.Passive (13G)Jul 16, 2025
- Cvi Investments, Inc.Passive (13G)Feb 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Steinhart Richard IDirector | May 12, 2026 | Grant | 10,000 | $0.00 |
| Chen Shu-ChihDirector | May 12, 2026 | Grant | 10,000 | $0.00 |
| Remmel H. LawrenceDirector | May 12, 2026 | Grant | 10,000 | $0.00 |
| Finn JonathanDirector | May 12, 2026 | Grant | 10,000 | $0.00 |
| Galli Stephen JDirector | May 12, 2026 | Grant | 10,000 | $0.00 |
| Cigler TessaDirector | May 12, 2026 | Grant | 10,000 | $0.00 |
| Quay Steven COfficer — President & CEO | Mar 27, 2026 | Grant | 65,000 | $0.00 |
| Daniel Mark JamesOfficer — Chief Financial Officer | Mar 26, 2026 | Grant | 63,000 | $0.00 |
| Quay Steven COfficer — President & CEO | Jan 20, 2026 | Grant | 325,203 | $0.00 |
| Quay Steven COfficer — President & CEO | May 21, 2025 | Buy | 11,239 | $0.88 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 341,344 | 5.6 | +1.1% |
| Apr 30, 2026 | 337,509 | 6.8 | -4.1% |
| Apr 15, 2026 | 351,934 | 5.6 | +7.4% |
| Mar 31, 2026 | 327,683 | 4.5 | +2.3% |
| Mar 13, 2026 | 320,202 | 3.3 | -11.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 8, 2026
- Other material eventApr 16, 2026
- Entered a material agreement · Terminated a material agreementFeb 20, 2026
- Delisting / listing-standard noticeFeb 17, 2026
- Regulation FD disclosureFeb 11, 2026
- Modified shareholder rights · Amended charter or bylaws · Shareholder voteJan 26, 2026
- Results of operations · Regulation FD disclosureJan 9, 2026
- Other material eventJan 6, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.